Volume 22, Number 1—January 2016
Research
Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013
Ross L. Cameron
, Kimberley Kavanagh, Jiafeng Pan, John Love, Kate Cuschieri, Chris Robertson, Syed Ahmed, Timothy Palmer, and Kevin G.J. Pollock
, Kimberley Kavanagh, Jiafeng Pan, John Love, Kate Cuschieri, Chris Robertson, Syed Ahmed, Timothy Palmer, and Kevin G.J. Pollock
Table 7
Prevalence and odds of infection with high-risk HPV excluding vaccine and cross-protective types and for any HPV among nonvaccinated women, by study year, Scotland, 2009–2013*
| Study year | No. women | High-risk HPV excluding vaccine
and cross-protective types† |
Any HPV |
|||||
|---|---|---|---|---|---|---|---|---|
| No. pos | % Pos (95% CI) | OR (95% CI) | No. pos | % Pos (95% CI) | OR (95% CI) | |||
| 2009 | 1.652 | 473 | 28.6 (26.5–30.9) | 1 | 946 | 57.3 (54.9–59.6) | 1 | |
| 2010 | 1,012 | 338 | 33.4 (30.6–36.4) | 1.26 (1.07–1.5) | 578 | 57.1 (54.0–60.1) | 0.99 (0.85–1.16) | |
| 2011 | 557 | 210 | 37.7 (33.8–41.8) | 1.50 (1.22–1.83) | 354 | 59.5 (59.5–67.4) | 1.30 (1.07–1.59) | |
| 2012 | 245 | 90 | 36.7 (30.9–42.9) | 1.44 (1.09–1.91) | 166 | 61.7 (61.7–73.3) | 1.56 (1.18–2.09) | |
| 2013 | 198 | 65 | 32.8 (26.7–39.6) | 1.20 (0.87–1.64) | 118 | 52.6 (53.6–66.2) | 1.10 (0.82–1.49) | |
*HPV, human papillomavirus; OR, odds ratio; pos, positive.
†HPV 35, 39, 51, 52, 56, 58, 59, or 68.
Page created: December 18, 2015
Page updated: December 18, 2015
Page reviewed: December 18, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.